Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
International collaborative ovarian neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer
ISRCTN ISRCTN57157825
DOI 10.1186/ISRCTN57157825
ClinicalTrials.gov identifier
EudraCT number
Public title International collaborative ovarian neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer
Scientific title
Acronym N/A
Serial number at source ICON3
Study hypothesis To compare paclitaxel in combination with carboplatin versus a control treatment of either single agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin) as first-line treatment of patients with advanced ovarian cancer.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment International
Disease/condition/study domain Cancer
Participants - inclusion criteria 1. Chemotherapy indicated
2. No previous chemotherapy or radiotherapy
3. No contraindication to chemotherapy
Participants - exclusion criteria Does not meet inclusion criteria
Anticipated start date 27/03/1995
Anticipated end date 01/06/1998
Status of trial Completed
Patient information material
Target number of participants 2000
Interventions 1. One group receives paclitaxel in combination with carboplatin
2. The other group receives a control treatment of either single agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin)
Primary outcome measure(s) Survival time - Time to progression, Quality of life, Health Economics
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (MRC) (UK)
Trial website
Publications 2002 results in http://www.ncbi.nlm.nih.gov/pubmed/12241653
Contact name Ms  Claire  Amos
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 28/02/2001
Last edited 02/07/2009
Date ISRCTN assigned 28/02/2001
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.